MicroRNAs as Potential Pharmaco-Targets in Ischemia-Reperfusion Injury Compounded by Diabetes

Abstract

Background: Ischemia-Reperfusion (I/R) injury is the tissue damage that results from re-oxygenation of ischemic tissues. There are many players that contribute to I/R injury. One of these factors is the family of microRNAs (miRNAs), which are currently being heavily studied. This review aims to critically summarize the latest papers that attributed roles of certain miRNAs in I/R injury, particularly in diabetic conditions and dissect their potential as novel pharmacologic targets in the treatment and management of diabetes. Methods: PubMed was searched for publications containing microRNA and I/R, in the absence or presence of diabetes. All papers that provided sufficient evidence linking miRNA with I/R, especially in the context of diabetes, were selected. Several miRNAs are found to be either pro-apoptotic, as in the case of miR-34a, miR-144, miR-155, and miR-200, or anti-apoptotic, as in the case of miR-210, miR-21, and miR-146a. Here, we further dissect the evidence that shows diverse cell-context dependent effects of these miRNAs, particularly in cardiomyocytes, endothelial, or leukocytes. We also provide insight into cases where the possibility of having two miRNAs working together to intensify a given response is noted. Conclusions: This review arrives at the conclusion that the utilization of miRNAs as translational agents or pharmaco-targets in treating I/R injury in diabetic patients is promising and becoming increasingly clearer.

MicroRNAs in Cardiac Hypertrophy

“…In addition, experiencing the inevitable treatment-limiting side effects poses higher incidence of cardiovascular events. Emerging evidence provides the basis, and hence the raison d’etre , for considering miRNAs as attractive pharmaco-targets in cardiac hypertrophy [105]. The miRNAs tackled in this paper represent the most recently discovered in this field, as well as some of the most studied ones, a list of which is summarized in Table 1.…”

Remote Ischemic Preconditioning Protects Cisplatin-Induced Acute Kidney Injury through the PTEN/AKT Signaling Pathway

“…It was well documented that miRNAs are implicated in many cellular processes such as cell metabolism, division, differentiation, apoptosis, and autophagy [34]. Previously, miR-144 has been demonstrated as an effective upstream regulator of PTEN in distinct contexts, of which the expression also was frequently aberrant in disease animal models, such as I/R-induced cardiomyocyte injury [25].…”

Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs

“…The actions and synthesis of microRNAs are tightly regulated; their expression level gets altered in the disease condition including in diabetes and diabetic nephropathy [21][22][23][24][25][26]. MiR-let-7 family members were involved in the antifibrotic mechanism of AcSDKP [9] whereas, miR-29 family members were implicated in the antifibrotic mechanism of linagliptin (DPP-4 inhibitor) [11].…”